TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $500,211 | -39.6% | 55,952 | +3.8% | 0.00% | – |
| Q2 2023 | $828,104 | -32.0% | 53,913 | -0.5% | 0.00% | – |
| Q1 2023 | $1,218,441 | +55817.4% | 54,177 | -47.7% | 0.00% | -100.0% |
| Q4 2022 | $2,179 | -100.0% | 103,597 | -80.5% | 0.00% | -80.0% |
| Q3 2022 | $13,061,000 | -37.6% | 530,091 | -38.7% | 0.01% | -37.5% |
| Q2 2022 | $20,936,000 | -26.1% | 864,060 | -21.4% | 0.01% | -11.1% |
| Q1 2022 | $28,321,000 | -13.8% | 1,099,058 | +3.8% | 0.01% | -10.0% |
| Q4 2021 | $32,854,000 | +39.6% | 1,058,503 | +9.1% | 0.01% | +25.0% |
| Q3 2021 | $23,533,000 | +40.6% | 970,470 | -15.4% | 0.01% | +60.0% |
| Q2 2021 | $16,733,000 | -45.6% | 1,146,826 | -6.9% | 0.01% | -50.0% |
| Q1 2021 | $30,749,000 | -5.3% | 1,231,510 | +3.3% | 0.01% | -16.7% |
| Q4 2020 | $32,481,000 | – | 1,191,712 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |